相关实验视频

Updated: Jun 10, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

皮胺A-D,新型异类化物,具有来自Hypecoum erectum L L9的潜在PCSK9抑制活性

Yinling Wei^1,2, Hongyan Wen¹, Lian Yang¹

¹State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, China.

Natural products and bioprospecting

|October 15, 2024

概括

从Hypecoum erectum L中发现了四种新的异类类化合物.化合物4显示出PCSK9的抑制活性,为心血管疾病药物发现提供了潜力.

科学领域:

自然产品化学自然产品化学
药理学药理学是指药理学的学科.
药用化学医学化学

背景情况:

心血管疾病 (CVD) 构成了严重的健康负担.
蛋白转化酶亚素/素9型 (PCSK9) 是胆固醇代谢的关键调节剂,也是心血管疾病的治疗点.
自然产品是新药发现的丰富来源.

研究的目的:

从Hypecoum erectum L.中分离和描述新的化合物.
评估孤立化合物作为PCSK9抑制剂在心血管疾病治疗中的潜力.

主要方法:

使用HRESIMS,NMR和X射线衍射的化物的隔离和结构阐明.
生物化学试验 (SPR,西斑) 来评估PCSK9的抑制活性.
分子对接研究,以预测结合相互作用.

主要成果:

发现了四种新的异类类化合物,即类类类化合物AD-1D (1-4).
化合物4表现出PCSK9抑制活性,其K_D值为59.9μM.
化合物4增加了LDLR水平,并与PCSK9.9形成稳定的相互作用.
为新化合物提出了一个可信的生物合成途径.

结论:

皮胺A-D是一种来自Hypecoum erectum L. 的新型异类化物.
化合物4显示出有前途的PCSK9抑制活性,表明对心血管疾病的潜在治疗应用.
为了药物开发,需要对化合物4进行进一步的研究.

关键词:

直体 (hypecoum erectum L. L. L.) 的意思是说,直体 (hypecoum erectum L.) 的意思是说,直体 (hypecoum erectum L.) 的意思是说,直体 (hypecoum erectum) 的意思是说,直体 (hypecoum erectum) 的意思是说,直体 (hypecoum erectum) 的意思是说,直体 (hypecoum erectum) 的意思是说,直体 (hypecoum erectum) 的意思是说,直体 (hypecoum erectum) 的意思是说,直体 (hypecoum erectum).催乳胺 A-D 催乳胺 A-D 异类类化合物异类类化合物抑制PCSK9的发生.

更多相关视频

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Author Spotlight: Discovering New Alkaloids in Plants with Advanced Mass Spectrometry Techniques

Author Spotlight: Discovering New Alkaloids in Plants with Advanced Mass Spectrometry Techniques

Published on: March 8, 2024

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...